Abstract:Objective The incidence and mortality of lung cancer rank first among malignant tumors, and its long treatment cycle will bring serious economic burdens to lung cancer patients and their families. There are few studies on the prognosis of lung cancer and insurance policies. This article explores the relationship between the lung cancer-specific death and public health insurance, self-paying rate, and the joint effect of public health insurance and self-paying rate. Materials and Methods A prospective longitudinal cohort study was conducted in Chongqing, China from 2013 to 2019. The selected subjects were patients with C33–C34 coded according to the tenth edition of the International Classification of Diseases (ICD-10), aged 20 years or older. We conduct a subgroup analysis based on public health insurance types and self-paying rates. After following the inclusion and exclusion criteria, the chi-square test was used to describe the demographic and clinical characteristics of patients with different insurance types and different self-paying rates. Multivariate logistic regression was used to analyze the relationship between patients with different insurance types, self-paying rates, and lung cancer treatment methods. Finally, the Cox proportional hazard model and the competitive risk model are used to calculate the cumulative hazard ratio of all-cause death and lung cancer-specific death for different insurance types and different self-paying rate groups. Results A total of 12,464 patients with lung cancer were included in this study. During the follow-up period (median 13 months, interquartile range 5.6–25.2 months), 5,803 deaths were observed, of which 3,781 died of lung cancer. Compared with patients who received urban resident-based basic medical insurance (URBMI), patients who received urban employee-based basic medical insurance (UEBMI) had a 38.1% higher risk of lung cancer-specific death (Hazard Ratios (HRs) = 1.381, 95% confidence interval (CI): 1.293–1.476, P < 0.005), Compared with patients with insufficient self-paying rate, patients with a higher self-paying rate had a 40.2% lower risk of lung cancer-specific death (HRs = 0.598, 95% CI: 0.557–0.643, P < 0.005). Every 10% increase in self-paying rate of URBMI reduces the risk of lung cancer-specific death by 17.6%, while every 10% increase in self-paying rate of UEBMI reduces the risk of lung cancer-specific death by 18.0%. Conclusions The National Medical Security Administration should, under the condition of limited medical insurance funds, try to include the original self-paid anti-tumor drugs into the national medical insurance coverage. This can not only reduce the mortality rate of lung cancer patients, but also reduce the family burden of lung cancer patients. On the other hand, high-risk groups should increase their awareness of lung cancer screening and actively participate in the national cancer screening project led by the state.

Analysis on the Data of Special Medical Insurance Management for Malignant Tumor in Chongqing in 2015-2016

Second Primary Malignancy among Malignant Solid Tumor Survivors Aged 85 Years and Older

Disparities of sex on cancer incidence and mortality in Jiashan county, Zhejiang province,1990-2014

Analysis of the Onset and Mortality of Common Malignant Tumors Among Registered Residents in Xishan District in 2016

Enzyme immunoassay for serum lidocaine in antiarrhythmic therapy.

Analysis of clinical epidemiology and pathological characteristics of multiple primary malignant tumors accompanied with colorectal malignant tumors

13637 CLINICAL CASE ANALYSIS OF NEW-ONSET MALIGNANT TUMOR AND INTERVENTION

Cancer incidence and mortality in China, 2015

Time trends of major cancers incidence and mortality in Guangzhou, China 2004–2015: A Joinpoint and Age–Period–Cohort Analysis

Analysis of malignant tumor incidence in Jing' an Temple community of Shanghai from 2002 to 2011

Lung Cancer-Specific Mortality Risk and Public Health Insurance: A Prospective Cohort Study in Chongqing, Southwest China

Cancer Incidence and Age Distribution in Women

Analysis of the disease burden trend of malignant tumors of the female reproductive system in China from 2006 to 2020

Analysis on Malignancies Induced Life Lost for the Major Sites from 2000 to 2004 in Qidong City

Stages of change for moderate-intensity physical activity in deprived neighborhoods.

Temporal Trends in the Incidence and Mortality of Skin Malignant Melanoma in China from 1990 to 2019

Lung Cancer in Young Patients Aged from 15 to 44 Years: Incidence Trend, Current Status and Survival Analysis from 2002 to 2005.

Cancer incidence and mortality in China, 2016

Multicenter Analysis of Lung Cancer Patients Younger Than 45 Years in Shanghai.

Analysis on Incidence and Mortality Trends and Age–Period–Cohort of Breast Cancer in Chinese Women from 1990 to 2019

National age-specific mortality trends for cervical and breast cancers in urban-rural areas of China from 2009 to 2021: a population-based analysis